RNUGF Stock - ReNeuron Group plc
Unlock GoAI Insights for RNUGF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $530,000 | $403,000 | $257,000 | $6.07M | $49,000 |
| Gross Profit | $-3,933,000 | $-7,665,000 | $-9,246,000 | $-10,270,000 | $-16,197,000 |
| Gross Margin | -742.1% | -1902.0% | -3597.7% | -169.3% | -33055.1% |
| Operating Income | $-7,115,000 | $-11,228,000 | $-12,914,000 | $-14,409,000 | $-18,282,000 |
| Net Income | $-5,408,000 | $-9,689,000 | $-11,347,000 | $-11,412,000 | $-14,292,000 |
| Net Margin | -1020.4% | -2404.2% | -4415.2% | -188.2% | -29167.3% |
| EPS | $-0.09 | $-0.17 | $-0.29 | $-0.35 | $-0.44 |
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized packages of information released by CTX cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
Visit WebsiteEarnings History & Surprises
RNUGFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2024 | Nov 11, 2024 | — | — | — | — |
Q3 2024 | Aug 21, 2024 | — | — | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.06 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.05 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.06 | — | — |
Q1 2022 | Mar 31, 2022 | $-0.15 | $-0.10 | +31.0% | ✓ BEAT |
Q3 2021 | Sep 30, 2021 | — | $-0.12 | — | — |
Q1 2021 | Mar 31, 2021 | $-0.18 | $-0.10 | +41.0% | ✓ BEAT |
Q3 2020 | Sep 30, 2020 | — | $-0.28 | — | — |
Q1 2020 | Mar 31, 2020 | $-0.34 | $-0.28 | +15.7% | ✓ BEAT |
Q3 2019 | Sep 30, 2019 | $-0.20 | $-0.15 | +24.6% | ✓ BEAT |
Q1 2019 | Mar 31, 2019 | — | $-0.37 | — | — |
Q3 2018 | Sep 30, 2018 | — | $-0.22 | — | — |
Q1 2018 | Mar 31, 2018 | — | $-0.36 | — | — |
Q3 2017 | Sep 30, 2017 | — | $-0.41 | — | — |
Q1 2017 | Mar 31, 2017 | — | $-0.31 | — | — |
Q3 2016 | Sep 30, 2016 | — | $-0.32 | — | — |
Q1 2016 | Mar 31, 2016 | — | $-0.31 | — | — |
Q3 2015 | Sep 30, 2015 | — | $-0.33 | — | — |
Q1 2015 | Mar 31, 2015 | — | $-0.40 | — | — |
Latest News
Frequently Asked Questions about RNUGF
What is RNUGF's current stock price?
What is the analyst price target for RNUGF?
What sector is ReNeuron Group plc in?
What is RNUGF's market cap?
Does RNUGF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to RNUGF for comparison